|
|
 Previous Article | Table of Contents | Next Article 
Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous
T-cell lymphoma [see comments]
TM Kuzel, A Hurria, E Samuelson, MS Tallman, HH Roenigk , AW Rademaker and ST Rosen
Department of Medicine, Robert H. Lurie Cancer Center of Northwestern
University, Chicago, IL, USA.
We investigated the efficacy of 2-chlorodeoxyadenosine (2-CdA) therapy in
patients with mycosis fungoides (MF) and the Sezary syndrome (SS). Between
February 1991 and November 1993, 21 patients with relapsed or refractory
MF/SS were treated with 2-CdA. 2-CdA was administered by continuous
intravenous infusion at a dose of 0.1 mg/kg/d for 7 days initially (13
patients), but was subsequently reduced to 5 days (nine patients) due to
hematologic toxicity. All patients had failed to respond to at least one
prior treatment for MF/SS (median number of total prior therapies, five;
median number of systemic prior therapies, three) and had an Eastern
Cooperative Oncology Group performance status of two or better. Cycles were
administered at 28-day intervals. Assessable patients received at least 5
days of 2-CdA. Fourteen patients received more than one cycle of 2-CdA. An
overall response rate of 28% was achieved. Three patients (14%) had a
complete response with a median duration of 4.5 months (range, 2.5 to 16).
Three (14%) had a partial response with a median duration of 2 months
(range, 2 to 4). Fifteen patients (72%) had no response. The most
significant toxicities encountered were bone marrow suppression (62% of
patients) and infectious complications (62% of patients). Thirty-eight
percent of patients experienced no toxicity from 2-CdA. 2-CdA has activity
as a single agent in patients with previously treated relapsed MF/SS.
Studies in less heavily pretreated individuals with 2-CdA alone or in
combination will be undertaken.
Volume 87,
Issue 3,
pp. 906-911,
02/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. M. Prince, S. Whittaker, and R. T. Hoppe
How I treat mycosis fungoides and Sezary syndrome
Blood,
November 12, 2009;
114(20):
4337 - 4353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, et al.
Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
J. Clin. Oncol.,
September 20, 2007;
25(27):
4293 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood,
June 1, 2003;
101(11):
4267 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
J. Clin. Oncol.,
August 15, 2000;
18(15):
2908 - 2925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Trautinger, J. Schwarzmeier, H. Honigsmann, and R. M. Knobler
Low-Dose 2-Chlorodeoxyadenosine for the Treatment of Mycosis Fungoides
Arch Dermatol,
October 1, 1999;
135(10):
1279 - 1280.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
J. M. Zaucha, K. Lewandowski, A. Hellmann, H. Pawlik, A. Siedlewicz;, T. M. Kuzel, and M. S. Tallman
2-Chlorodeoxyadenosine Treatment in the Sezary Syndrome
Blood,
February 15, 1997;
89(4):
1462 - 1464.
[Full Text]
[PDF]
|
|
|
|
|
